Vertex’s Price Tag For Taking More Control Of CRISPR-Partnered Candidate: At Least $900m

Change To Partnership Comes After First Positive Pivotal Data For Blood Disorders

20 Apr 2021

Vertex and partner CRISPR Therapeutics hope CDX001 can offer a single-use curative regimen for sickle cell disease and beta thalassemia patients. A regulatory filing is possible within 18-24 months.

Sickle cell anemia, 3D illustration showing blood vessel with normal and deformated crescent-like red blood cells — Vertex thinks CTX001 may offer a cure for sickle cell disease, beta thalassemia

Vertex Pharmaceuticals Incorporated increased its wager on a gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia on 20 April, paying CRISPR Therapeutics AG $900m up front to increase both its responsibility and its economic share of CTX001, now in potentially registrational studies for both of the rare hemoglobinopathies.

Vertex told Scrip that if the two ongoing studies continue at their current pace with further positive results, CTX001 could...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

11 Jun 2025

• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

05 Jun 2025

• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

14 May 2025

• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

09 May 2025

• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.